TheraRadar

NovoCure

Pre-Approval PRO BETA

Also known as: NovoCure GmbH, NovoCure Ltd.

🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 2/3/2025

15
Total Trials
7
Phase 3
7
Phase 2
2
Recruiting
164
Score

Pipeline by Phase

Phase 3
7
Phase 2
7
Phase 1
1

Therapeutic Focus

NSCLC Non-small Cell Lung Cancer Glioblastoma Multiforme Glioblastoma Nonsmall Cell Lung Cancer

Clinical Trials (15)

NCT06556563 Phase 3 RECRUITING

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Started: 2/3/2025

NCT06216301 Phase 3 RECRUITING

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Started: 7/31/2024

NCT02973789 Phase 3 COMPLETED

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Started: 12/1/2016

NCT02831959 Phase 3 COMPLETED

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Started: 7/1/2016

NCT03377491 Phase 3 COMPLETED

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Started: 5/10/2018

NCT03940196 Phase 3 COMPLETED

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Started: 3/22/2019

NCT00916409 Phase 3 COMPLETED

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Started: 6/1/2009

NCT06558799 Phase 2 TERMINATED

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Started: 10/14/2024

NCT04892472 Phase 2 TERMINATED

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Started: 7/12/2021

NCT04492163 Phase 2 COMPLETED

Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM

Started: 7/14/2020

NCT06390059 Phase 2 COMPLETED

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Started: 8/28/2023

NCT03606590 Phase 2 COMPLETED

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Started: 2/15/2019

NCT02397928 Phase 2 COMPLETED

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Started: 2/1/2015

NCT00749346 Phase 1 COMPLETED

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

Started: 5/1/2008

NCT01756729 Phase 4 TERMINATED

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

Started: 12/1/2012

Drug Candidates

Immune checkpoint inhibitors or docetaxel Platinum based chemotherapy
Activity Status: Slowing
Last Trial Started: 2/3/2025
Last Trial Ended: 2/23/2026
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.